Scientists created a new therapeutic design for glioblastoma, the deadliest form of brain cancer. The lab engineered molecules called trispecifics that connect cancer-killing T cells with not just one ...
Lantern Pharma shares were up 6% to $3.34 after the company said the Food and Drug Administration has granted fast-track designation for the investigational drug candidate LP-184 for the treatment of ...